AIM: To investigate the impact of high-dose hepatitis B immunoglobulin (HBIG) on hepatocellular carcinoma (HCC) and hepatitis B virus (HBV) recurrence and overall survival after living donor liver transplantation (LDLT). METHODS: We investigated 168 patients who underwent LDLT due to HCC, and who were HBV-DNA/hepatitis B e antigen (HBeAg) -positive, from January 2008 to December 2013. After assessing whether the patients met the Milan criteria, they were assigned to the low-dose HBIG group and high-dose HBIG group. Using the propensity score 1:1 matching method, 38 and 18 pairs were defined as adhering to and not adhering to the Milan criteria. For each pair, HCC recurrence, HBV recurrence and overall survival were analyzed by the Kaplan-Meier method and the log rank test according to the HBIG dose. RESULTS: Among those who met the Milan criteria, the 6-mo, 1-year, and 3-year HCC recurrence-free survival rates were 88.9%, 83.2%, and 83.2% in the low-dose HBIG group and 97.2%, 97.2%, and 97.2% in the high-dose HBIG group, respectively (P = 0.042). In contrast, among those who did not meet the Milan criteria, HCC recurrence did not differ according to the HBIG dose (P = 0.937). Moreover, HBV recurrence and overall survival did not differ according to the HBIG dose among those who met (P = 0.317 and 0.190, respectively) and did not meet (P = 0.350 and 0.987, respectively) the Milan criteria. CONCLUSION: High-dose HBIG therapy can reduce HCC recurrence in HBV-DNA/HBeAg-positive patients after LDLT.
AIM: To investigate the impact of high-dose hepatitis B immunoglobulin (HBIG) on hepatocellular carcinoma (HCC) and hepatitis B virus (HBV) recurrence and overall survival after living donor liver transplantation (LDLT). METHODS: We investigated 168 patients who underwent LDLT due to HCC, and who were HBV-DNA/hepatitis B e antigen (HBeAg) -positive, from January 2008 to December 2013. After assessing whether the patients met the Milan criteria, they were assigned to the low-dose HBIG group and high-dose HBIG group. Using the propensity score 1:1 matching method, 38 and 18 pairs were defined as adhering to and not adhering to the Milan criteria. For each pair, HCC recurrence, HBV recurrence and overall survival were analyzed by the Kaplan-Meier method and the log rank test according to the HBIG dose. RESULTS: Among those who met the Milan criteria, the 6-mo, 1-year, and 3-year HCC recurrence-free survival rates were 88.9%, 83.2%, and 83.2% in the low-dose HBIG group and 97.2%, 97.2%, and 97.2% in the high-dose HBIG group, respectively (P = 0.042). In contrast, among those who did not meet the Milan criteria, HCC recurrence did not differ according to the HBIG dose (P = 0.937). Moreover, HBV recurrence and overall survival did not differ according to the HBIG dose among those who met (P = 0.317 and 0.190, respectively) and did not meet (P = 0.350 and 0.987, respectively) the Milan criteria. CONCLUSION: High-dose HBIG therapy can reduce HCC recurrence in HBV-DNA/HBeAg-positive patients after LDLT.
Entities:
Keywords:
Hepatitis B e antigen; Hepatitis B immune globulin; Hepatitis B virus-DNA; Hepatocellular carcinoma; Liver transplantation
Authors: R Perrillo; J Rakela; J Dienstag; G Levy; P Martin; T Wright; S Caldwell; E Schiff; R Gish; J P Villeneuve; G Farr; G Anschuetz; L Crowther; N Brown Journal: Hepatology Date: 1999-05 Impact factor: 17.425
Authors: D Samuel; A Bismuth; D Mathieu; J L Arulnaden; M Reynes; J P Benhamou; C Brechot; H Bismuth Journal: Lancet Date: 1991-04-06 Impact factor: 79.321
Authors: Thomas Steinmüller; Daniel Seehofer; Nada Rayes; Andrea R Müller; Utz Settmacher; Sven Jonas; Ruth Neuhaus; Thomas Berg; Uwe Hopf; Peter Neuhaus Journal: Hepatology Date: 2002-06 Impact factor: 17.425
Authors: Hubert Darius J Daniel; John G Fletcher; George M Chandy; Priya Abraham Journal: Indian J Med Microbiol Date: 2009 Apr-Jun Impact factor: 0.985
Authors: E Regalia; L R Fassati; U Valente; A Pulvirenti; I Damilano; G Dardano; F Montalto; J Coppa; V Mazzaferro Journal: J Hepatobiliary Pancreat Surg Date: 1998